Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 6/20 | 1.00 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.63 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.63 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.63 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.63 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.63 |
| ▸ | RAB9A | P51151 | 7/20 | 0.60 |
| ▸ | NPC1 | O15118 | 5/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.60 |
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.58 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 3/20 | 0.55 |
| ▸ | BCAT1 | P54687 | 1/20 | 0.55 |
| ▸ | CSNK2A1 | P68400 | 3/20 | 0.54 |
| ▸ | CSNK2A2 | P19784 | 2/20 | 0.54 |
| ▸ | CSNK2B | P67870 | 2/20 | 0.54 |
| ▸ | CSNK2A3 | Q8NEV1 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29523120 | 1.00 | PIM1 (1.00) | PIM1GRIN1GRIN2AGRIN2BGRIN2C | |
| Hydrochloric Acid SCHEMBL10423094 | 0.98 | PIM1 (0.96) | PIM1GRIN1GRIN2AGRIN2BGRIN2C | |
| SCHEMBL6232284 | 0.91 | PIM1 (0.82) | PIM1GRIN1GRIN2AGRIN2BGRIN2C | |
| SCHEMBL2705460 | 0.85 | PIM1 (0.74) | PIM1GRIN1GRIN2AGRIN2BGRIN2C | |
| SCHEMBL2197426 | 0.85 | PIM1 (0.74) | PIM1GRIN1GRIN2AGRIN2BGRIN2C | |
| SCHEMBL1297716 | 0.84 | PIM1 (0.72) | PIM1GRIN1GRIN2AGRIN2BGRIN2C | |
| SCHEMBL3619989 | 0.84 | PIM1 (0.72) | PIM1GRIN1GRIN2AGRIN2BGRIN2C | |
| SCHEMBL6240008 | 0.82 | PIM1 (0.70) | PIM1GRIN1GRIN2AGRIN2BGRIN2C | |
| SCHEMBL1602739 | 0.82 | RAB9A (0.69) | PIM1GRIN1GRIN2AGRIN2BGRIN2C | |
| SCHEMBL30629233 | 0.82 | RAB9A (0.69) | PIM1GRIN1GRIN2AGRIN2BGRIN2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 208 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113943304-B | Pim-1 kinase targeted phthalocyanine-5-bromo-1-benzofuran-2-carboxylic acid complex, and preparation method and application thereof | 福州大学 | 2024-01-30 | — | — | CN | claimed |
| CN-113943304-A | Phthalocyanine-5-bromo-1-benzofuran-2-carboxylic acid complex targeting Pim-1 kinase and preparation method and application thereof | 福州大学 | 2022-01-18 | — | — | CN | claimed |
| US-8598175-B2 | Heteroarylamide pyrimidone derivatives | SANOFI (FR) | 2013-12-03 | — | — | US | claimed |
| EP-2162443-B1 | HETEROARYLAMIDE-SUBSTITUTED PYRIMIDONE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SANOFI SA (FR) | 2013-07-31 | — | — | EP | claimed |
| JP-4511835-B2 | — | — | 2010-07-28 | — | — | JP | claimed |
| US-20100081677-A1 | HETEROARYLAMIDE PYRIMIDONE DERIVATIVES | SANOFI-AVENTIS (FR) | 2010-04-01 | — | — | US | claimed |
| EP-2162443-A2 | HETEROARYLAMIDE-SUBSTITUTED PYRIMIDONE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | Sanofi-Aventis (FR) | 2010-03-17 | — | — | EP | claimed |
| EP-2121635-A2 | SUBSTITUTED HETEROARYL PYRIDOPYRIMIDONE DERIVATIVES | Sanofi-Aventis (FR) | 2009-11-25 | — | — | EP | claimed |
| WO-2008155666-A2 | HETEROARYLAMIDE-SUBSTITUTED PYRIMIDONE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SANOFI-AVENTIS (FR) | 2008-12-24 | — | — | WO | claimed |
| EP-1992621-A1 | Heteroarylamide-substituted pyrimidone derivatives for the treatment of neurodegenerative diseases | Sanofi-Aventis (FR) | 2008-11-19 | — | — | EP | claimed |
| CN-100413882-C | Linear basic compounds having NK-2 antagonistic activity and formulations thereof | MENARINI RICERCHE SPA (IT) | 2008-08-27 | — | — | CN | claimed |
| WO-2008078196-A2 | SUBSTITUTED HETEROARYL PYRIDOPYRIMIDONE DERIVATIVES | SANOFI-AVENTIS (FR) | 2008-07-03 | — | — | WO | claimed |
| EP-1939187-A1 | Substituted heteroaryl pyridopyrimidone derivatives | Sanofi-Aventis (FR) | 2008-07-02 | — | — | EP | claimed |
| US-7273856-B2 | Linear basic compounds having NK-2 antagonist activity and formulations thereof | MENARINI RICERCHE S.P.A. (IT) | 2007-09-25 | — | — | US | claimed |
| EP-1442050-B1 | LINEAR BASIC COMPOUNDS HAVING NK-2 ANTAGONIST ACTIVITY AND FORMULATIONS THEREOF | MALESCI SAS (IT) | 2006-09-13 | — | — | EP | claimed |
| CN-1578786-A | Linear basic compounds having NK-2 antagonistic activity and formulations thereof | MENARINI RICERCHE SPA (IT) | 2005-02-09 | — | — | CN | claimed |
| US-20040259930-A1 | Linear basic compounds having nk-2 antagonist activity and formulations thereof | MALESCI INSTITUTO FARMACOBIOLOGICO S.P.A. (IT) | 2004-12-23 | — | — | US | claimed |
| EP-1442050-A2 | LINEAR BASIC COMPOUNDS HAVING NK-2 ANTAGONIST ACTIVITY AND FORMULATIONS THEREOF | MALESCI ISTITUTO FARMACOBIOLOGICO S.p.A. (IT) | 2004-08-04 | — | — | EP | claimed |
| WO-2003037916-A2 | LINEAR BASIC COMPOUNDS HAVING NK-2 ANTAGONIST ACTIVITY AND FORMULATIONS THEREOF | MALESCI ISTITUTO FARMACOBIOLOGICO S.P.A. (IT) | 2003-05-08 | — | — | WO | claimed |
| US-12590062-B2 | PD-1/PD-L1 inhibitors | GILEAD SCIENCES, INC. (US) | 2026-03-31 | — | — | US | disclosed |
| EP-4171563-B1 | TETRAZOLE DERIVATIVES AS TRPA1 INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2025-08-06 | — | — | EP | disclosed |
| US-20250214977-A1 | STAT6 INHIBITORS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-07-03 | — | — | US | disclosed |
| CN-115703736-B | Multi-target inhibitor targeting HDAC and NAD synthesis and application thereof | 中国海洋大学 | 2025-05-16 | — | — | CN | disclosed |
| US-20250092019-A1 | TETRAZOLE DERIVATIVES AS TRPA1 INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2025-03-20 | — | — | US | disclosed |
| EP-4228755-B1 | TETRAZOLE DERIVATIVES AS TRPA1 INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2024-12-11 | — | — | EP | disclosed |
| WO-2024238406-A1 | FUROPYRIDINE COMPOUNDS AS P53 MUTANT STABILIZER AND USES THEREOF | FRONTIER MEDICINES CORPORATION (US) | 2024-11-21 | — | — | WO | disclosed |
| CN-118878461-A | PD-1/PD-L1 inhibitors | 吉利德科学公司 | 2024-11-01 | — | — | CN | disclosed |
| US-20240352032-A1 | TETRAZOLE DERIVATIVES AS TRPA1 INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2024-10-24 | — | — | US | disclosed |
| US-20240327418-A1 | MULTI-TARGET INHIBITOR TARGETING HDAC AND NAD SYNTHESIS AND USE OF MULTI-TARGET INHIBITOR | OCEAN UNIVERSITY OF CHINA (CN) | 2024-10-03 | — | — | US | disclosed |
| CN-117624141-A | Colorimetric fluorescent probe for high-selectivity sensitive detection of formaldehyde, preparation method and application | 吉林化工学院 | 2024-03-01 | — | — | CN | disclosed |
| CN-113943304-B | Pim-1 kinase targeted phthalocyanine-5-bromo-1-benzofuran-2-carboxylic acid complex, and preparation method and application thereof | 福州大学 | 2024-01-30 | — | — | CN | disclosed |
| CN-113943304-B | Pim-1 kinase targeted phthalocyanine-5-bromo-1-benzofuran-2-carboxylic acid complex, and preparation method and application thereof | 福州大学 | 2024-01-30 | — | — | CN | disclosed |
| CN-113943304-B | Pim-1 kinase targeted phthalocyanine-5-bromo-1-benzofuran-2-carboxylic acid complex, and preparation method and application thereof | 福州大学 | 2024-01-30 | — | — | CN | disclosed |
| US-11884652-B2 | Tetrazole derivatives as TRPA1 inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2024-01-30 | — | — | US | disclosed |
| EP-4228755-A1 | TETRAZOLE DERIVATIVES AS TRPA1 INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2023-08-23 | — | — | EP | disclosed |
| US-20230257395-A1 | TETRAZOLE DERIVATIVES AS TRPA1 INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2023-08-17 | — | — | US | disclosed |
| US-20230257395-A1 | TETRAZOLE DERIVATIVES AS TRPA1 INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2023-08-17 | — | — | US | disclosed |
| US-20230257395-A1 | TETRAZOLE DERIVATIVES AS TRPA1 INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2023-08-17 | — | — | US | disclosed |
| EP-4216946-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | Achillion Pharmaceuticals, Inc. (US) | 2023-08-02 | — | — | EP | disclosed |
| CN-116437913-A | Pharmaceutical compounds for treating complement-mediated disorders | 艾其林医药公司 | 2023-07-14 | — | — | CN | disclosed |
| CN-116348471-A | Tetrazole derivatives as TRPA1 inhibitors | 勃林格殷格翰国际有限公司 | 2023-06-27 | — | — | CN | disclosed |
| CN-114409663-B | Zinc phthalocyanine 3-chloro-6 methylbenzo [ b ] thiophene-2-carboxylic acid conjugates targeting Mcl-1 enzyme and methods of making the same | 福州大学 | 2023-05-30 | — | — | CN | disclosed |
| US-11661430-B2 | Tetrazole derivatives as TRPA1 inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2023-05-30 | — | — | US | disclosed |
| US-11661430-B2 | Tetrazole derivatives as TRPA1 inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2023-05-30 | — | — | US | disclosed |
| US-11661430-B2 | Tetrazole derivatives as TRPA1 inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2023-05-30 | — | — | US | disclosed |
| EP-4171563-A1 | TETRAZOLE DERIVATIVES AS TRPA1 INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2023-05-03 | — | — | EP | disclosed |
| CN-115803029-A | Tetrazole derivatives as TRPA1 inhibitors | 勃林格殷格翰国际有限公司 | 2023-03-14 | — | — | CN | disclosed |
| CN-115703736-A | Multi-target inhibitors targeting HDAC and NAD synthesis and uses thereof | 中国海洋大学 | 2023-02-17 | — | — | CN | disclosed |
| WO-2023011416-A1 | MULTI-TARGET INHIBITOR TARGETING HDAC AND NAD SYNTHESIS AND USE OF MULTI-TARGET INHIBITOR | 中国海洋大学 | 2023-02-09 | — | — | WO | disclosed |
| US-20220304984-A1 | AMINO ACID TRANSPORT INHIBITORS AND THE USES THEREOF | VANDERBILT UNIVERSITY | 2022-09-29 | — | — | US | disclosed |
| EP-4026835-A2 | PD-1/PD-L1 INHIBITORS | Gilead Sciences, Inc. (US) | 2022-07-13 | — | — | EP | disclosed |
| CN-114409663-A | Mcl-1 enzyme targeted zinc phthalocyanine 3-chloro-6 methylbenzo [ b ] thiophene-2-carboxylic acid conjugates and methods of making the same | 福州大学 | 2022-04-29 | — | — | CN | disclosed |
| WO-2022079091-A1 | TETRAZOLE DERIVATIVES AS TRPA1 INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2022-04-21 | — | — | WO | disclosed |
| WO-2022079091-A1 | TETRAZOLE DERIVATIVES AS TRPA1 INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2022-04-21 | — | — | WO | disclosed |
| EP-3983084-A1 | AMINO ACID TRANSPORT INHIBITORS AND THE USES THEREOF | Vanderbilt University (US) | 2022-04-20 | — | — | EP | disclosed |
| US-20220112210-A1 | TETRAZOLE DERIVATIVES AS TRPA1 INHIBITORS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2022-04-14 | — | — | US | disclosed |
| CN-114222729-A | Amino acid transport inhibitors and uses thereof | 范德比尔特大学 | 2022-03-22 | — | — | CN | disclosed |
| CN-113943304-A | Phthalocyanine-5-bromo-1-benzofuran-2-carboxylic acid complex targeting Pim-1 kinase and preparation method and application thereof | 福州大学 | 2022-01-18 | — | — | CN | disclosed |
| US-20220002270-A1 | TETRAZOLE DERIVATIVES AS TRPA1 INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2022-01-06 | — | — | US | disclosed |
| WO-2022002782-A1 | TETRAZOLE DERIVATIVES AS TRPA1 INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2022-01-06 | — | — | WO | disclosed |
| US-20220002270-A1 | TETRAZOLE DERIVATIVES AS TRPA1 INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2022-01-06 | — | — | US | disclosed |
| WO-2022002782-A1 | TETRAZOLE DERIVATIVES AS TRPA1 INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2022-01-06 | — | — | WO | disclosed |
| CN-106478564-B | Cathepsin K inhibitors and uses thereof | 广东东阳光药业有限公司 | 2021-11-12 | — | — | CN | disclosed |
| US-20210323922-A1 | PD-1/PD-L1 INHIBITORS | GILEAD SCIENCES, INC. (US) | 2021-10-21 | — | — | US | disclosed |
| CN-112135825-A | Plasma kallikrein inhibitors and uses thereof | 夏尔人类遗传性治疗公司 | 2020-12-25 | — | — | CN | disclosed |
| WO-2020252353-A1 | AMINO ACID TRANSPORT INHIBITORS AND THE USES THEREOF | VANDERBILT UNIVERSITY (US) | 2020-12-17 | — | — | WO | disclosed |
| WO-2020205467-A1 | STAT3 PROTEIN DEGRADERS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2020-10-08 | — | — | WO | disclosed |
| WO-2020198435-A1 | SMALL MOLECULE DEGRADERS OF STAT3 | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2020-10-01 | — | — | WO | disclosed |
| EP-3612525-A1 | PD-1/PD-L1 INHIBITORS | Gilead Sciences, Inc. (US) | 2020-02-26 | — | — | EP | disclosed |
| CN-110799509-A | PD-1/PD-L1 inhibitors | 吉利德科学公司 | 2020-02-14 | — | — | CN | disclosed |
| CN-106715422-B | Indene derivative, preparation method and the pharmaceutical composition for being used to prevent or treat retinal disease comprising it as active constituent | 忠南大学校产学协力团 | 2019-11-19 | — | — | CN | disclosed |
| EP-3176163-B1 | NOVEL INDENE DERIVATIVE, PREPARATION METHOD FOR SAME, AND PHARMACEUTICAL COMPOSITION, FOR PREVENTING OR TREATING RETINAL DISEASES, CONTAINING SAME AS ACTIVE INGREDIENT | IAC IN NAT UNIV CHUNGNAM (KR) | 2019-04-17 | — | — | EP | disclosed |
| CN-106397377-B | The method of fluorine on a kind of electron rich five-ring heterocycles acid and its derivative decarboxylation | 中南大学 | 2019-04-05 | — | — | CN | disclosed |
| US-20190002444-A1 | CRYSTALLINE FORMS OF VILAZODONE HYDROCHLORIDE AND VILAZODONE FREE BASE | DR. REDDY'S LABORATORIES LIMITED (IN) | 2019-01-03 | — | — | US | disclosed |
| EP-3401315-A1 | FXR RECEPTOR MODULATOR, PREPARATION METHOD THEREFOR, AND USES THEREOF | Guangzhou Henovcom Bioscience Co. Ltd. (CN) | 2018-11-14 | — | — | EP | disclosed |
| WO-2018195321-A1 | PD-1/PD-L1 INHIBITORS | GILEAD SCIENCES, INC. (US) | 2018-10-25 | — | — | WO | disclosed |
| US-20180305315-A1 | PD-1/PD-L1 INHIBITORS | GILEAD SCIENCES, INC. | 2018-10-25 | — | — | US | disclosed |
| US-10011590-B2 | Crystalline forms of vilazodone hydrochloride and vilazodone free base | DR. REDDY'S LABORATORIES LIMITED (IN) | 2018-07-03 | — | — | US | disclosed |
| CN-107383024-B | The class compound of fused tricyclic containing imidazoles and its application | 广州必贝特医药技术有限公司 | 2018-06-08 | — | — | CN | disclosed |
| US-9869027-B2 | Cleaning composition and method of manufacturing metal wiring using the same | SAMSUNG DISPLAY CO., LTD. (KR) | 2018-01-16 | — | — | US | disclosed |
| CN-107383024-A | The class compound of fused tricyclic containing imidazoles and its application | 广州必贝特医药技术有限公司 | 2017-11-24 | — | — | CN | disclosed |
| US-20170217939-A1 | CRYSTALLINE FORMS OF VILAZODONE HYDROCHLORIDE AND VILAZODONE FREE BASE | DR. REDDY'S LABORATORIES LIMITED (IN) | 2017-08-03 | — | — | US | disclosed |
| EP-3176163-A1 | NOVEL INDENE DERIVATIVE, PREPARATION METHOD FOR SAME, AND PHARMACEUTICAL COMPOSITION, FOR PREVENTING OR TREATING RETINAL DISEASES, CONTAINING SAME AS ACTIVE INGREDIENT | The Industry & Academic Cooperation in Chungnam National University (IAC) (KR) | 2017-06-07 | — | — | EP | disclosed |
| US-20170152268-A1 | NOVEL INDENE DERIVATIVE, PREPARATION METHOD FOR SAME, AND PHARMACEUTICAL COMPOSITION, FOR PREVENTING OR TREATING RETINAL DISEASES, CONTAINING SAME AS ACTIVE INGREDIENT | MOTHER'S PHARMACEUTICAL CO., LTD. (KR) | 2017-06-01 | — | — | US | disclosed |
| CN-106715422-A | Novel indene derivative, preparation method for same, and pharmaceutical composition, for preventing or treating retinal diseases, containing same as active ingredient | 忠南大学校产学协力团 | 2017-05-24 | — | — | CN | disclosed |
| CN-106478564-A | Cathepsin K inhibitor and application thereof | 广东东阳光药业有限公司 | 2017-03-08 | — | — | CN | disclosed |
| CN-106397377-A | Electron-rich five-membered heterocyclic acid and method for decarboxylation and fluorination of derivative thereof | 中南大学 | 2017-02-15 | — | — | CN | disclosed |
| EP-1373204-B1 | HETEROCYCLIC COMPOUNDS | JANSSEN PHARMACEUTICALS INC (US) | 2016-10-26 | — | — | EP | disclosed |
| WO-2016128987-A1 | A PROCESS FOR PREPARATION OF 2-BENZOFURANCARBOXAMIDE, 5-[4-[4-(5CYANO-1H-INDOL-3-YL)BUTYL]-1-PIPERAZINYL] FREE BASE AND ITS HYDROCHLORIDE SALT | HARMAN FINOCHEM LIMITED (IN) | 2016-08-18 | — | — | WO | disclosed |
| US-20160230289-A1 | CLEANING COMPOSITION AND METHOD OF MANUFACTURING METAL WIRING USING THE SAME | SAMSUNG DISPLAY CO LTD (KR) | 2016-08-11 | — | — | US | disclosed |
| US-9340759-B2 | Cleaning composition and method of manufacturing metal wiring using the same | SAMSUNG DISPLAY CO., LTD. (KR) | 2016-05-17 | — | — | US | disclosed |
| US-20160122337-A1 | 2-HETEROARYL CARBOXAMIDES | BAYER HEALTHCARE AG (DE) | 2016-05-05 | — | — | US | disclosed |
| CN-103467422-B | A kind of method preparing vilazodone intermediate 5-piperazinyl-2-acyl substituted cumarone | SHAANXI BUCHANG HIGH-TECH PHARMACEUTICAL CO., LTD. (CN) | 2016-02-24 | — | — | CN | disclosed |
| US-9266892-B2 | Fused pyrazoles as FGFR inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2016-02-23 | — | — | US | disclosed |
| CN-103450125-B | A kind of 5-replaces the synthetic method of benzofuran-2-carboxylic acid and derivative thereof | CHIMICA LABORATORIES CO., LTD. (CN) | 2016-01-13 | — | — | CN | disclosed |
| US-20150289512-A1 | METHOD FOR PROMOTING PLANT GROWTH | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2015-10-15 | — | — | US | disclosed |
| US-20150289512-A1 | METHOD FOR PROMOTING PLANT GROWTH | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2015-10-15 | — | — | US | disclosed |
| US-9067931-B2 | 2-heteroaryl carboxamides | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-06-30 | — | — | US | disclosed |
| US-20150136728-A1 | CLEANING COMPOSITION AND METHOD OF MANUFACTURING METAL WIRING USING THE SAME | SAMSUNG DISPLAY CO., LTD. (KR) | 2015-05-21 | — | — | US | disclosed |
| US-20150126525-A1 | CRYSTALLINE FORMS OF VILAZODONE HYDROCHLORIDE AND VILAZODONE FREE BASE | REDDYS LAB LTD DR (IN) | 2015-05-07 | — | — | US | disclosed |
| US-20140350008-A1 | 2-HETEROARYL CARBOXAMIDES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-11-27 | — | — | US | disclosed |
| US-8884017-B2 | 2-heteroarylcarboxylic acid amides | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-11-11 | — | — | US | disclosed |
| US-20140171405-A1 | Fused Pyrazoles as FGFR Inhibitors | INCYTE CORPORATION (US) | 2014-06-19 | — | — | US | disclosed |
| WO-2014073627-A1 | METHOD FOR PROMOTING PLANT GROWTH | 住友化学株式会社 (JP) | 2014-05-15 | — | — | WO | disclosed |
| US-8598175-B2 | Heteroarylamide pyrimidone derivatives | SANOFI (FR) | 2013-12-03 | — | — | US | disclosed |
| WO-2013168126-A1 | CRYSTALLINE FORMS OF VILAZODONE HYDROCHLORIDE AND VILAZODONE FREE BASE | DR.REDDYS LABORATORIES LIMITED (IN) | 2013-11-14 | — | — | WO | disclosed |
| US-8541579-B2 | Substituted diketopiperazines as oxytocin antagonists | GLAXO GROUP LIMITED (GB) | 2013-09-24 | — | — | US | disclosed |
| EP-2162443-B1 | HETEROARYLAMIDE-SUBSTITUTED PYRIMIDONE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SANOFI SA (FR) | 2013-07-31 | — | — | EP | disclosed |
| US-20130131338-A1 | SUBSTITUTED DIKETOPIPERAZINES AS OXYTOCIN ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2013-05-23 | — | — | US | disclosed |
| US-8367673-B2 | Substituted diketopiperazines as oxytocin antagonists | GLAXO GROUP LIMITED (GB) | 2013-02-05 | — | — | US | disclosed |
| US-20120258964-A1 | 2-HETEROARYL CARBOXAMIDES | BAYER SCHERING PHARMA AG (DE) | 2012-10-11 | — | — | US | disclosed |
| US-20120202842-A1 | 2-HETEROARYLCARBOXYLIC ACID AMIDES | BAYER SCHERING PHARMA AG (DE) | 2012-08-09 | — | — | US | disclosed |
| WO-2011159781-A2 | BITTER TASTE MODULATORS | SENOMYX, INC. (US) | 2011-12-22 | — | — | WO | disclosed |
| US-8076355-B2 | 2-heteroarylcarboxylic acid amides | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-12-13 | — | — | US | disclosed |
| US-20110263591-A1 | 2-HETEROARYL CARBOXAMIDES | BAYER SCHERING PHARMA AG (DE) | 2011-10-27 | — | — | US | disclosed |
| US-7977485-B2 | 2-heteroaryl carboxamides | BAYER SCHERING PHARMA AKTIENGESELLSHAFT (DE) | 2011-07-12 | — | — | US | disclosed |
| US-20100222378-A1 | 2-HETEROARYLCARBOXYLIC ACID AMIDES | BAYER SCHERING PHARMA AG (DE) | 2010-09-02 | — | — | US | disclosed |
| US-7732477-B2 | N-(1-azabicyclo[2.2.2]oct-3-yl)-heteroaryl carboxamides; alpha 7-nicotinic acetylcholine receptors (nAChR) agonists; improving perception, concentration, learning and memory; neuropathic pain; acute and chronic pain | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-06-08 | — | — | US | disclosed |
| US-20100081677-A1 | HETEROARYLAMIDE PYRIMIDONE DERIVATIVES | SANOFI-AVENTIS (FR) | 2010-04-01 | — | — | US | disclosed |
| US-20090318479-A1 | SUBSTITUTED RING FUSED AZINES AND THEIR USE IN CANCER THERAPY | AUCKLAND UNISERVICES LIMITED | 2009-12-24 | — | — | US | disclosed |
| EP-2121635-A2 | SUBSTITUTED HETEROARYL PYRIDOPYRIMIDONE DERIVATIVES | Sanofi-Aventis (FR) | 2009-11-25 | — | — | EP | disclosed |
| US-20090186867-A1 | Substituted Diketopiperazines As Oxytocin Antagonists | GLAXO GROUP LIMITED | 2009-07-23 | — | — | US | disclosed |
| US-7514437-B2 | Substituted diketopiperazines as oxytocin antagonists | SMITHKLINE BEECHAM CORP. (US) | 2009-04-07 | — | — | US | disclosed |
| EP-1992621-A1 | Heteroarylamide-substituted pyrimidone derivatives for the treatment of neurodegenerative diseases | Sanofi-Aventis (FR) | 2008-11-19 | — | — | EP | disclosed |
| CN-100413882-C | Linear basic compounds having NK-2 antagonistic activity and formulations thereof | MENARINI RICERCHE SPA (IT) | 2008-08-27 | — | — | CN | disclosed |
| US-20080194539-A1 | Phenyl Diazepane Carboxamides and Annelated Phenyl Piperazine Carboxamides Containing Oxygen and Used as Dopamine D3 Antagonists | SCHWARZ PHARMA AG (DE) | 2008-08-14 | — | — | US | disclosed |
| US-7405299-B2 | Compounds as pharmaceutical agents | ELI LILLY AND COMPANY (US) | 2008-07-29 | — | — | US | disclosed |
| WO-2008078196-A2 | SUBSTITUTED HETEROARYL PYRIDOPYRIMIDONE DERIVATIVES | SANOFI-AVENTIS (FR) | 2008-07-03 | — | — | WO | disclosed |
| EP-1939187-A1 | Substituted heteroaryl pyridopyrimidone derivatives | Sanofi-Aventis (FR) | 2008-07-02 | — | — | EP | disclosed |
| EP-1458393-B1 | SUBSTITUTED DIKETOPIPERAZINES AS OXYTOCIN ANTAGONISTS | GLAXO GROUP LTD (GB) | 2008-06-25 | — | — | EP | disclosed |
| US-20080119485-A1 | Novel Benzofurans and Indols | ACTIVE BIOTECH AB (SE) | 2008-05-22 | — | — | US | disclosed |
| US-7339059-B2 | Benzofurans and indols | ACTIVE BIOTECH AB (SE) | 2008-03-04 | — | — | US | disclosed |
| EP-1761524-B1 | PHENYL DIAZEPANE CARBOXAMIDES AND ANNELATED PHENYL PIPERAZINE CARBOXAMIDES CONTAINING OXYGEN AND USED AS DOPAMINE D3 ANTAGONISTS | SANOL ARZNEI SCHWARZ GMBH (DE) | 2007-11-21 | — | — | EP | disclosed |
| US-7273856-B2 | Linear basic compounds having NK-2 antagonist activity and formulations thereof | MENARINI RICERCHE S.P.A. (IT) | 2007-09-25 | — | — | US | disclosed |
| US-7208491-B2 | N-monoacylated o-phenylenediamines | HOFFMANN-LA ROCHE INC. (US) | 2007-04-24 | — | — | US | disclosed |
| EP-1761524-A1 | PHENYL DIAZEPANE CARBOXAMIDES AND ANNELATED PHENYL PIPERAZINE CARBOXAMIDES CONTAINING OXYGEN AND USED AS DOPAMINE D3 ANTAGONISTS | SCHWARZ PHARMA AG (DE) | 2007-03-14 | — | — | EP | disclosed |
| EP-1461335-B1 | 2-HETEROARYLCARBOXYLIC ACID AMIDES | BAYER HEALTHCARE AG (DE) | 2007-02-28 | — | — | EP | disclosed |
| EP-1718612-A1 | NOVEL BENZOFURANS AND INDOLS | Active Biotech AB (SE) | 2006-11-08 | — | — | EP | disclosed |
| EP-1515967-B1 | 2-HETEROARYL CARBOXAMIDES | BAYER HEALTHCARE AG (DE) | 2006-11-02 | — | — | EP | disclosed |
| EP-1442050-B1 | LINEAR BASIC COMPOUNDS HAVING NK-2 ANTAGONIST ACTIVITY AND FORMULATIONS THEREOF | MALESCI SAS (IT) | 2006-09-13 | — | — | EP | disclosed |
| EP-1685836-A2 | Antifungal activity of dicationic molecules | UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2006-08-02 | — | — | EP | disclosed |
| US-20060160877-A1 | 2-Heteroaryl carboxamides | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2006-07-20 | — | — | US | disclosed |
| WO-2006072430-A1 | PHENYL DIAZEPANE CARBOXAMIDES AND ANNELATED PHENYL PIPERAZINE CARBOXAMIDES CONTAINING OXYGEN AND USED AS DOPAMINE D3 ANTAGONISTS | SCHWARZ PHARMA AG (DE) | 2006-07-13 | — | — | WO | disclosed |
| CN-1256334-C | Alkoxycarbonylaminobenzoic acid or alkoxycarbonylaminotetrazolylphenyl derivatives as IP antagonists | HOFFMANN LA ROCHE (CH) | 2006-05-17 | — | — | CN | disclosed |
| EP-1368345-B1 | ALKOXYCARBONYLAMINO HETEROARYL CARBOXYLIC ACID DERIVATIVES AS IP ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2006-03-22 | — | — | EP | disclosed |
| US-20060058295-A1 | Novel compounds as pharmaceutical agents | ELI LILLY AND COMPANY (US) | 2006-03-16 | — | — | US | disclosed |
| US-6989384-B2 | Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis | AGOURON PHARMACEUTICALS, INC. (US) | 2006-01-24 | — | — | US | disclosed |
| EP-1379516-B1 | ALKOXYCARBONYLAMINO BENZOIC ACID OR ALKOXYCARBONYLAMINO TETRAZOLYL PHENYL DERIVATIVES AS IP ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2005-11-16 | — | — | EP | disclosed |
| EP-1594857-A2 | N-MONOACYLATED O-PHENYLENEDIAMINES AS ANTI-CANCER AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-11-16 | — | — | EP | disclosed |
| CN-1694703-A | Use of indolyl derivatives for the manufacture of a medicament for the treatment allergic rhinitis | JANSSEN PHARMACEUTICA NV (BE) | 2005-11-09 | — | — | CN | disclosed |
| US-20050197343-A1 | Utilization of heteroarene carboxamide as dopamine-d3 ligands for the treatment of cns diseases | SCHWARZ PHARMA AG (DE) | 2005-09-08 | — | — | US | disclosed |
| US-20050192288-A1 | Benzofuran-2-yl-carbonyl- and indol-2-yl-carbonyl-trans-2,5-dimethyl-piperazine derivatives; rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosus, inflammatory bowel disease, asthma; inhibit the interaction between inflammatory chemokines and their receptor | ACTIVE BIOTECH AB (SE) | 2005-09-01 | — | — | US | disclosed |
| WO-2005080336-A1 | NOVEL BENZOFURANS AND INDOLS | ACTIVE BIOTECH AB (SE) | 2005-09-01 | — | — | WO | disclosed |
| EP-1551406-A1 | USE OF INDOLYL DERIVATIVES FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF ALLERGIC RHINITIS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-07-13 | — | — | EP | disclosed |
| US-20050148572-A1 | Substituted diketopiperazines as oxytocin antagonists | GLAXO GROUP LIMITED (GB) | 2005-07-07 | — | — | US | disclosed |
| EP-1320523-B1 | BRANCHED CHAIN AMINO ACID-DEPENDENT AMINOTRANSFERASE INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | WARNER LAMBERT CO (US) | 2005-06-22 | — | — | EP | disclosed |
| US-6903086-B2 | Alkoxycarbonylamino benzoic acid or alkoxycarbonylamino tetrazolyl phenyl derivatives as IP antagonists | SYNTEX (U.S.A.) LLC (US) | 2005-06-07 | — | — | US | disclosed |
| US-20050119325-A1 | N-(1-azabicyclo[2.2.2]oct-3-yl)-heteroaryl carboxamides; alpha 7-nicotinic acetylcholine receptors (nAChR) agonists; improving perception, concentration, learning and memory; neuropathic pain; acute and chronic pain | FMR LLC | 2005-06-02 | — | — | US | disclosed |
| US-20050085487-A1 | Heterocyclic compounds | CARRUTHERS NICHOLAS I (US) | 2005-04-21 | — | — | US | disclosed |
| US-20050080121-A1 | Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis | AGOURON PHARMACEUTICALS, INC. | 2005-04-14 | — | — | US | disclosed |
| EP-1515967-A1 | 2-HETEROARYL CARBOXAMIDES | Bayer HealthCare AG (DE) | 2005-03-23 | — | — | EP | disclosed |
| CN-1578786-A | Linear basic compounds having NK-2 antagonistic activity and formulations thereof | MENARINI RICERCHE SPA (IT) | 2005-02-09 | — | — | CN | disclosed |
| US-20050004167-A1 | Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of neurodegenerative diseases | WARNER-LAMBERT COMPANY LLC | 2005-01-06 | — | — | US | disclosed |
| CN-1182129-C | Benzopyran derivatives having leukotriene-antagonistic action | ������ʵ���ҹ�˾ | 2004-12-29 | — | — | CN | disclosed |
| US-20040259930-A1 | Linear basic compounds having nk-2 antagonist activity and formulations thereof | MALESCI INSTITUTO FARMACOBIOLOGICO S.P.A. (IT) | 2004-12-23 | — | — | US | disclosed |
| US-6803362-B2 | ANTIHISTAMINES SUCH AS (5-CHLORO-1H-INDOL-2-YL)-(4-METHYL-PIPERAZIN-1-YL)-METHANONE, USED AS ANTIINFLAMMATORY, ANTIARTHRITIC OR BRONCHODILATOR AGENTS AND/OR IMMUNOLOGY MODULATORS | ORTHO-MCNEIL PHARMACEUTICAL INC. | 2004-10-12 | — | — | US | disclosed |
| EP-1461335-A1 | 2-HETEROARYLCARBOXYLIC ACID AMIDES | Bayer HealthCare AG (DE) | 2004-09-29 | — | — | EP | disclosed |
| WO-2004069133-A2 | N-MONOACYLATED O-PHENYLENEDIAMINES AS ANTI -CANCER AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-08-19 | — | — | WO | disclosed |
| US-20040157841-A1 | inhibition of histone deacetylase; for inhibiting cell proliferation; cancer therapy | HOFFMANN-LA ROCHE INC. | 2004-08-12 | — | — | US | disclosed |
| EP-1442050-A2 | LINEAR BASIC COMPOUNDS HAVING NK-2 ANTAGONIST ACTIVITY AND FORMULATIONS THEREOF | MALESCI ISTITUTO FARMACOBIOLOGICO S.p.A. (IT) | 2004-08-04 | — | — | EP | disclosed |
| US-20040132715-A1 | Method to treat allergic rhinitis | DUNFORD PAUL J (US) | 2004-07-08 | — | — | US | disclosed |
| WO-2004022061-A1 | USE OF INDOLYL DERIVATIVES FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT ALLERGIC RHINITIS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2004-03-18 | — | — | WO | disclosed |
| EP-1379516-A1 | ALKOXYCARBONYLAMINO BENZOIC ACID OR ALKOXYCARBONYLAMINO TETRAZOLYL PHENYL DERIVATIVES AS IP ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-01-14 | — | — | EP | disclosed |
| EP-1373204-A2 | HETEROCYCLIC COMPOUNDS | Ortho-McNeil Pharmaceutical, Inc. (US) | 2004-01-02 | — | — | EP | disclosed |
| WO-2003104227-A1 | 2-HETEROARYL CARBOXAMIDES | BAYER HEALTHCARE AG (DE) | 2003-12-18 | — | — | WO | disclosed |
| EP-1368345-A1 | ALKOXYCARBONYLAMINO HETEROARYL CARBOXYLIC ACID DERIVATIVES AS IP ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-12-10 | — | — | EP | disclosed |
| US-20030207893-A1 | Heterocyclic compounds | ORTHO MCNEIL PHARMACEUTICAL, INC. | 2003-11-06 | — | — | US | disclosed |
| US-6632825-B2 | Picornaviral 3C protease enzyme inhibitors; amide ester or amide acid derivatives | AGOURON PHARMACEUTICALS, INC. | 2003-10-14 | — | — | US | disclosed |
| WO-2003055878-A1 | 2-HETEROARYLCARBOXYLIC ACID AMIDES | BAYER HEALTHCARE AG (DE) | 2003-07-10 | — | — | WO | disclosed |
| EP-1320523-A2 | BRANCHED CHAIN AMINO ACID-DEPENDENT AMINOTRANSFERASE INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | Warner-Lambert Company LLC (US) | 2003-06-25 | — | — | EP | disclosed |
| US-6569860-B2 | Alkoxycarbonylamino-heteroaryl carboxylic acid derivatives useful for treating the disorders of the urinary tract, pain, inflammation, respiratory states, edema formation, hypotensive vascular diseases, pain and allergies | ROćHE PALO ALTO LLC | 2003-05-27 | — | — | US | disclosed |
| WO-2003037916-A2 | LINEAR BASIC COMPOUNDS HAVING NK-2 ANTAGONIST ACTIVITY AND FORMULATIONS THEREOF | MALESCI ISTITUTO FARMACOBIOLOGICO S.P.A. (IT) | 2003-05-08 | — | — | WO | disclosed |
| US-20020169171-A1 | Alkoxycarbonylamino heteroaryl carboxylic acid derivatives as IP antagonists | SYNTEX (USA) LLC | 2002-11-14 | — | — | US | disclosed |
| US-20020165235-A1 | Alkoxycarbonylamino benzoic acid or alkoxycarbonylamino tetrazolyl phenyl derivatives as IP antagonists | SYNTEX (U.S.A.) LLC | 2002-11-07 | — | — | US | disclosed |
| WO-2002072548-A2 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS HISTAMINE H4 LIGANDS. | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2002-09-19 | — | — | WO | disclosed |
| WO-2002070500-A1 | ALKOXYCARBONYLAMINO BENZOIC ACID OR ALKOXYCARBONYLAMINO TETRAZOLYL PHENYL DERIVATIVES AS IP ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-09-12 | — | — | WO | disclosed |
| WO-2002070514-A1 | ALKOXYCARBONYLAMINO HETEROARYL CARBOXYLIC ACID DERIVATIVES AS IP ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-09-12 | — | — | WO | disclosed |
| EP-0888327-B1 | BENZOPYRAN DERIVATIVES HAVING LEUKOTRIENE-ANTAGONISTIC ACTION | MENARINI LAB (ES) | 2002-06-12 | — | — | EP | disclosed |
| US-20020061916-A1 | Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis | AGOURON PHARMACEUTICALS, INC. | 2002-05-23 | — | — | US | disclosed |
| WO-2002024672-A2 | BRANCHED CHAIN AMINO ACID-DEPENDENT AMINOTRANSFERASE INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | WARNER-LAMBERT COMPANY LLC (US) | 2002-03-28 | — | — | WO | disclosed |
| US-6326395-B1 | AMIDINE OR AMIDE SUBSTITUTED FURAN DERIVATIVES | DUKE UNIVERSITY | 2001-12-04 | — | — | US | disclosed |
| EP-1143959-A2 | ANTIFUNGAL ACTIVITY OF DICATIONIC MOLECULES | UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2001-10-17 | — | — | EP | disclosed |
| EP-1091958-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2001-04-18 | — | — | EP | disclosed |
| WO-2000015212-A2 | ANTIFUNGAL ACTIVITY OF DICATIONIC MOLECULES | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2000-03-23 | — | — | WO | disclosed |
| WO-2000001692-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2000-01-13 | — | — | WO | disclosed |
| US-5990142-A | ANTIINFLAMMATORY AGENTS AND ANTIALLERGENS HAVING GOOD ORAL ADSORPTION AND BIOAVAILABILITY; CARDIOTONIC AND ANTIISCHEMIC AGENTS | LABORATORIOS MENARINI S.A. (ES) | 1999-11-23 | — | — | US | disclosed |
| CN-1214048-A | Benzopyran derivatives having leukotriene-antagonistic action | LABROATORIOS MENARINI S A (ES) | 1999-04-14 | — | — | CN | disclosed |
| EP-0888327-A1 | BENZOPYRAN DERIVATIVES HAVING LEUKOTRIENE-ANTAGONISTIC ACTION | LABORATORIOS MENARINI S.A. (ES) | 1999-01-07 | — | — | EP | disclosed |
| WO-1997034885-A1 | BENZOPYRAN DERIVATIVES HAVING LEUKOTRIENE-ANTAGONISTIC ACTION | LABORATORIOS MENARINI S.A. (ES) | 1997-09-25 | — | — | WO | disclosed |
| US-5354769-A | Treatment of anorexia | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 1994-10-11 | — | — | US | disclosed |
| US-5310930-A | Cyclization of the carboximidate salt | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S) (FR) | 1994-05-10 | — | — | US | disclosed |
| EP-0533265-A1 | Process of making substituted azetidinones | MERCK & CO. INC. (US) | 1993-03-24 | — | — | EP | disclosed |
| EP-0527189-A1 | NOVEL CC-1065 ANALOGS | PHARMACIA & UPJOHN COMPANY (US) | 1993-02-17 | — | — | EP | disclosed |
| US-5149838-A | Intermediates for substituted azetidinones useful as anti-inflammatory and antidegenerative agents | MERCK & CO., INC. (US) | 1992-09-22 | — | — | US | disclosed |
| US-4374990-A | ANTIDEPRESSANTS | HOECHST AKTIENGESELLSCHAFT (DE) | 1983-02-22 | — | — | US | disclosed |
| US-4115569-A | PARASITICIDES | HOECHST AKTIENGESELLSCHAFT (DE) | 1978-09-19 | — | — | US | disclosed |
| US-4009994-A | Process and product of optical brightening with quaternized benzofuranyl-benzimidazoles | CIBA-GEIGY CORPORATION (US) | 1977-03-01 | — | — | US | disclosed |
| US-3940417-A | Quaternised benzofuranyl-benzimidazoles | CIBA-GEIGY CORPORATION (US) | 1976-02-24 | — | — | US | disclosed |
| US-3940417-A | Quaternised benzofuranyl-benzimidazoles | CIBA-GEIGY CORPORATION (US) | 1976-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (48 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020165235-A1 | Alkoxycarbonylamino benzoic acid or alkoxycarbonylamino tetrazolyl phenyl derivatives as IP antagonists | GPBAR1, GABRP, TBXA2R | PIM1 2308/4885GRIN1 166/4885GRIN2A 255/4885 |
| US-20140171405-A1 | Fused Pyrazoles as FGFR Inhibitors | FGFR1, FGFR3, FGFR2 | PIM1 145/4885GRIN1 1861/4885GRIN2A 2889/4885 |
| US-20210323922-A1 | PD-1/PD-L1 INHIBITORS | CD274, PDCD1, PDCD1LG2 | PIM1 128/4885GRIN1 1091/4885GRIN2A 2818/4885 |
| US-20050197343-A1 | Utilization of heteroarene carboxamide as dopamine-d3 ligands for the treatment of cns diseases | SLC6A3, DRD2, ADH1A | PIM1 3854/4885GRIN1 114/4885GRIN2A 36/4885 |
| US-20060058295-A1 | Novel compounds as pharmaceutical agents | TGFB1, TGFB2, TGFBR1 | PIM1 880/4885GRIN1 4169/4885GRIN2A 4344/4885 |
| US-20050192288-A1 | Benzofuran-2-yl-carbonyl- and indol-2-yl-carbonyl-trans-2,5-dimethyl-piperazine derivatives; rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosus, inflammatory bowel disease, asthma; inhibit the interaction between inflammatory chemokines and their receptor | CXCR1, CCR2, CXCR5 | PIM1 3164/4885GRIN1 2163/4885GRIN2A 2607/4885 |
| US-20100222378-A1 | 2-HETEROARYLCARBOXYLIC ACID AMIDES | HCAR2, HCAR1, GRIN2A | PIM1 4272/4885GRIN1 22/4885GRIN2A 3/4885 |
| US-20140350008-A1 | 2-HETEROARYL CARBOXAMIDES | GRIN2A, CNR2, GRIN2C | PIM1 3148/4885GRIN1 14/4885GRIN2A 1/4885 |
| US-20130131338-A1 | SUBSTITUTED DIKETOPIPERAZINES AS OXYTOCIN ANTAGONISTS | OXTR, AVPR2, CRH | PIM1 3683/4885GRIN1 739/4885GRIN2A 516/4885 |
| US-20250092019-A1 | TETRAZOLE DERIVATIVES AS TRPA1 INHIBITORS | TRPA1, TRPV1, TRPV5 | PIM1 4664/4885GRIN1 71/4885GRIN2A 188/4885 |
| US-20150126525-A1 | CRYSTALLINE FORMS OF VILAZODONE HYDROCHLORIDE AND VILAZODONE FREE BASE | VIL1, VMA21, PYGL | PIM1 543/4885GRIN1 1138/4885GRIN2A 573/4885 |
| US-20050004167-A1 | Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of neurodegenerative diseases | BCAT1, BCAT2, ABAT | PIM1 2992/4885GRIN1 165/4885GRIN2A 143/4885 |
| US-20120258964-A1 | 2-HETEROARYL CARBOXAMIDES | GRIN2A, CNR2, GRIN2C | PIM1 3148/4885GRIN1 14/4885GRIN2A 1/4885 |
| US-20050080121-A1 | Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis | PRCP, RNPEP, SARNP | PIM1 4059/4885GRIN1 4139/4885GRIN2A 4342/4885 |
| US-11884652-B2 | Tetrazole derivatives as TRPA1 inhibitors | TRPA1, TRPV1, TRPV5 | PIM1 4664/4885GRIN1 71/4885GRIN2A 188/4885 |
| US-20240352032-A1 | TETRAZOLE DERIVATIVES AS TRPA1 INHIBITORS | TRPA1, TRPV1, TRPV5 | PIM1 4664/4885GRIN1 71/4885GRIN2A 188/4885 |
| US-20050148572-A1 | Substituted diketopiperazines as oxytocin antagonists | OXTR, AVPR2, AVPR1B | PIM1 3318/4885GRIN1 613/4885GRIN2A 489/4885 |
| US-20230257395-A1 | TETRAZOLE DERIVATIVES AS TRPA1 INHIBITORS | TRPA1, TRPV1, TRPV5 | PIM1 4664/4885GRIN1 71/4885GRIN2A 188/4885 |
| US-20050119325-A1 | N-(1-azabicyclo[2.2.2]oct-3-yl)-heteroaryl carboxamides; alpha 7-nicotinic acetylcholine receptors (nAChR) agonists; improving perception, concentration, learning and memory; neuropathic pain; acute and chronic pain | CHRNA2, CHRNA7, CHRNA3 | PIM1 4868/4885GRIN1 57/4885GRIN2A 38/4885 |
| US-20170217939-A1 | CRYSTALLINE FORMS OF VILAZODONE HYDROCHLORIDE AND VILAZODONE FREE BASE | VIL1, VMA21, PYGL | PIM1 545/4885GRIN1 913/4885GRIN2A 463/4885 |
| US-20220304984-A1 | AMINO ACID TRANSPORT INHIBITORS AND THE USES THEREOF | SLC1A5, SLC7A11, SLC3A2 | PIM1 3113/4885GRIN1 669/4885GRIN2A 653/4885 |
| US-20170152268-A1 | NOVEL INDENE DERIVATIVE, PREPARATION METHOD FOR SAME, AND PHARMACEUTICAL COMPOSITION, FOR PREVENTING OR TREATING RETINAL DISEASES, CONTAINING SAME AS ACTIVE INGREDIENT | RIPK1, RIPK2, RIPK3 | PIM1 406/4885GRIN1 1103/4885GRIN2A 2193/4885 |
| US-20160122337-A1 | 2-HETEROARYL CARBOXAMIDES | GRIN2A, CNR2, GRIN2C | PIM1 3148/4885GRIN1 14/4885GRIN2A 1/4885 |
| US-20020169171-A1 | Alkoxycarbonylamino heteroaryl carboxylic acid derivatives as IP antagonists | GPBAR1, GCGR, CNR1 | PIM1 2605/4885GRIN1 144/4885GRIN2A 184/4885 |
| US-20020061916-A1 | Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis | PRCP, RNASEL, RNASEH1 | PIM1 4118/4885GRIN1 4030/4885GRIN2A 4405/4885 |
| US-20060160877-A1 | 2-Heteroaryl carboxamides | GRIN2A, CNR2, GRIN2C | PIM1 3148/4885GRIN1 14/4885GRIN2A 1/4885 |
| US-10011590-B2 | Crystalline forms of vilazodone hydrochloride and vilazodone free base | VIL1, VMA21, PYGL | PIM1 545/4885GRIN1 913/4885GRIN2A 463/4885 |
| US-20220112210-A1 | TETRAZOLE DERIVATIVES AS TRPA1 INHIBITORS | TRPA1, TRPV1, TRPV5 | PIM1 4664/4885GRIN1 71/4885GRIN2A 188/4885 |
| US-20250214977-A1 | STAT6 INHIBITORS AND USES THEREOF | STAT6, STAT5B, STAT5A | PIM1 29/4885GRIN1 4309/4885GRIN2A 4340/4885 |
| US-20240327418-A1 | MULTI-TARGET INHIBITOR TARGETING HDAC AND NAD SYNTHESIS AND USE OF MULTI-TARGET INHIBITOR | HDAC3, HDAC1, HDAC11 | PIM1 4487/4885GRIN1 760/4885GRIN2A 1366/4885 |
| US-12590062-B2 | PD-1/PD-L1 inhibitors | CD274, PDCD1LG2, PDCD1 | PIM1 2371/4885GRIN1 261/4885GRIN2A 587/4885 |
| US-20040259930-A1 | Linear basic compounds having nk-2 antagonist activity and formulations thereof | BDKRB2, BDKRB1, TACR2 | PIM1 3365/4885GRIN1 174/4885GRIN2A 186/4885 |
| US-20090318479-A1 | SUBSTITUTED RING FUSED AZINES AND THEIR USE IN CANCER THERAPY | TP53, AZI2, MCL1 | PIM1 1252/4885GRIN1 3827/4885GRIN2A 3217/4885 |
| US-20040132715-A1 | Method to treat allergic rhinitis | HRH2, HRH4, HRH1 | PIM1 4353/4885GRIN1 1051/4885GRIN2A 563/4885 |
| US-20040157841-A1 | inhibition of histone deacetylase; for inhibiting cell proliferation; cancer therapy | HDAC1, HDAC11, HDAC7 | PIM1 1950/4885GRIN1 1751/4885GRIN2A 3553/4885 |
| US-20050085487-A1 | Heterocyclic compounds | AADAC, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, NQO1 | PIM1 1753/4885GRIN1 2265/4885GRIN2A 1222/4885 |
| US-20120202842-A1 | 2-HETEROARYLCARBOXYLIC ACID AMIDES | HCAR2, HCAR1, GRIN2A | PIM1 4272/4885GRIN1 22/4885GRIN2A 3/4885 |
| US-20080119485-A1 | Novel Benzofurans and Indols | FOXM1, IKZF3, BRPF3 | PIM1 1938/4885GRIN1 2493/4885GRIN2A 4113/4885 |
| US-11661430-B2 | Tetrazole derivatives as TRPA1 inhibitors | TRPA1, TRPV1, TRPV5 | PIM1 4649/4885GRIN1 69/4885GRIN2A 179/4885 |
| US-20220002270-A1 | TETRAZOLE DERIVATIVES AS TRPA1 INHIBITORS | TRPA1, TRPV1, TRPV5 | PIM1 4664/4885GRIN1 71/4885GRIN2A 188/4885 |
| US-20110263591-A1 | 2-HETEROARYL CARBOXAMIDES | GRIN2A, CNR2, GRIN2C | PIM1 3148/4885GRIN1 14/4885GRIN2A 1/4885 |
| US-20080194539-A1 | Phenyl Diazepane Carboxamides and Annelated Phenyl Piperazine Carboxamides Containing Oxygen and Used as Dopamine D3 Antagonists | DRD3, DRD2, DRD1 | PIM1 725/4885GRIN1 167/4885GRIN2A 131/4885 |
| US-20100081677-A1 | HETEROARYLAMIDE PYRIMIDONE DERIVATIVES | DHFR, DPYD, HPRT1 | PIM1 1115/4885GRIN1 1000/4885GRIN2A 2246/4885 |
| US-20030207893-A1 | Heterocyclic compounds | AADAC, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, NQO1 | PIM1 1750/4885GRIN1 2264/4885GRIN2A 1223/4885 |
| US-20180305315-A1 | PD-1/PD-L1 INHIBITORS | CD274, PDCD1, PDCD1LG2 | PIM1 128/4885GRIN1 1091/4885GRIN2A 2818/4885 |
| US-20090186867-A1 | Substituted Diketopiperazines As Oxytocin Antagonists | OXTR, AVPR2, CRH | PIM1 3664/4885GRIN1 811/4885GRIN2A 600/4885 |
| US-20150289512-A1 | METHOD FOR PROMOTING PLANT GROWTH | FGF1, MKI67, FGF2 | PIM1 2283/4885GRIN1 1355/4885GRIN2A 3501/4885 |
| US-20190002444-A1 | CRYSTALLINE FORMS OF VILAZODONE HYDROCHLORIDE AND VILAZODONE FREE BASE | VIL1, VMA21, PYGL | PIM1 545/4885GRIN1 913/4885GRIN2A 463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.